These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1366 related articles for article (PubMed ID: 25679074)
1. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin. Tran K; Khan S; Taghizadehasl M; Palazzo F; Frilling A; Todd JF; Al-Nahhas A Hell J Nucl Med; 2015; 18(1):19-24. PubMed ID: 25679074 [TBL] [Abstract][Full Text] [Related]
2. Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Conry BG; Papathanasiou ND; Prakash V; Kayani I; Caplin M; Mahmood S; Bomanji JB Eur J Nucl Med Mol Imaging; 2010 Jan; 37(1):49-57. PubMed ID: 19662413 [TBL] [Abstract][Full Text] [Related]
3. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma. Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617 [TBL] [Abstract][Full Text] [Related]
4. Comparison of ⁶⁸Ga-DOTATATE PET-CT, ¹⁸F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma. Ozkan ZG; Kuyumcu S; Uzum AK; Gecer MF; Ozel S; Aral F; Adalet I Nucl Med Commun; 2015 Mar; 36(3):242-50. PubMed ID: 25369749 [TBL] [Abstract][Full Text] [Related]
5. Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Naswa N; Sharma P; Suman Kc S; Lata S; Kumar R; Malhotra A; Bal C Nucl Med Commun; 2012 Jul; 33(7):766-74. PubMed ID: 22531829 [TBL] [Abstract][Full Text] [Related]
6. The role of Şahin OE; Uslu-Beşli L; Asa S; Sağer S; Sönmezoğlu K Hell J Nucl Med; 2020; 23(3):321-329. PubMed ID: 33367304 [TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases. Mucha SA; Kunert-Radek J; Pomorski L Endokrynol Pol; 2006; 57(4):452-5. PubMed ID: 17006852 [TBL] [Abstract][Full Text] [Related]
11. [Evaluation of efficacy and clinical impact of 18F-FDG-PET in the diagnosis of recurrent medullary thyroid cancer with increased calcitonin and negative imaging test]. Gómez-Camarero P; Ortiz-de Tena A; Borrego-Dorado I; Vázquez-Albertino RJ; Navarro-González E; Ruiz-Franco-Baux JV; Cuenca-Cuenca JI Rev Esp Med Nucl Imagen Mol; 2012 Sep; 31(5):261-6. PubMed ID: 23067528 [TBL] [Abstract][Full Text] [Related]
12. The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study. Rubello D; Rampin L; Nanni C; Banti E; Ferdeghini M; Fanti S; Al-Nahhas A; Gross MD Eur J Surg Oncol; 2008 May; 34(5):581-6. PubMed ID: 17892923 [TBL] [Abstract][Full Text] [Related]
13. Role of [(18)F]FDG-PET/CT in the detection of occult recurrent medullary thyroid cancer. Skoura E; Rondogianni P; Alevizaki M; Tzanela M; Tsagarakis S; Piaditis G; Tolis G; Datseris IE Nucl Med Commun; 2010 Jun; 31(6):567-75. PubMed ID: 20335822 [TBL] [Abstract][Full Text] [Related]
14. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with Sampathirao N; Basu S J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019 [TBL] [Abstract][Full Text] [Related]
15. Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. Treglia G; Castaldi P; Villani MF; Perotti G; de Waure C; Filice A; Ambrosini V; Cremonini N; Santimaria M; Versari A; Fanti S; Giordano A; Rufini V Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):569-80. PubMed ID: 22223169 [TBL] [Abstract][Full Text] [Related]
16. [(68)Ga]DOTATATE PET/MRI and [(18)F]FDG PET/CT are complementary and superior to diffusion-weighted MR imaging for radioactive-iodine-refractory differentiated thyroid cancer. Vrachimis A; Stegger L; Wenning C; Noto B; Burg MC; Konnert JR; Allkemper T; Heindel W; Riemann B; Schäfers M; Weckesser M Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1765-72. PubMed ID: 27059853 [TBL] [Abstract][Full Text] [Related]
17. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Luster M; Karges W; Zeich K; Pauls S; Verburg FA; Dralle H; Glatting G; Buck AK; Solbach C; Neumaier B; Reske SN; Mottaghy FM Thyroid; 2010 May; 20(5):527-33. PubMed ID: 20450432 [TBL] [Abstract][Full Text] [Related]
18. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer. Kauhanen S; Schalin-Jäntti C; Seppänen M; Kajander S; Virtanen S; Schildt J; Lisinen I; Ahonen A; Heiskanen I; Väisänen M; Arola J; Korsoff P; Ebeling T; Sane T; Minn H; Välimäki MJ; Nuutila P J Nucl Med; 2011 Dec; 52(12):1855-63. PubMed ID: 22052128 [TBL] [Abstract][Full Text] [Related]
19. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors. Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768 [TBL] [Abstract][Full Text] [Related]
20. The role of PET-CT scan with somatostatin analogue labelled with gallium-68 (⁶⁸Ga-DOTA-TATE PET-CT) in diagnosing patients with disseminated medullary thyroid carcinoma (MTC). Pałyga I; Kowalska A; Gąsior-Perczak D; Tarnawska-Pierścińska M; Słuszniak J; Sygut J; Góźdź S Endokrynol Pol; 2010; 61(5):507-11. PubMed ID: 21049467 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]